BioMarin Pharmaceutical Inc. - Common Stock — Financial Statistics (NASDAQ:BMRN) | MetaTrader

Open full chart

News

BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55...

BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified

BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)

Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine (NYSE:NVO)

Tracking John Paulson’s Paulson & Company Portfolio: Q2 2026 Update (OTCMKTS:FNMA)

BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN)

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

BioMarin Stops Voxzogo Development for Noonan Syndrome

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript